Pfizer Stock Forecast for 2022 - 2025 - 2030
Updated on 05/25/2022
The average target price for Pfizer's stock set by sixteen renowned analysts in recent months is $55.00, representing a potential upside of approximately 2.98% from its last closing price if met by 2023. This estimation is based on a high estimate of $75.00 and a low estimate of $48.00. If you are looking to invest in the stock, it's important to research and compare different companies.
2.98% Upside
Pfizer Fair Value Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's Fair Value has grown by 47.33%, from $41.58 to $61.26. For the next year, analysts are expecting Fair Value to reach an impressive $98.96 – an increase of 61.54%. By 2030, professionals predict that Pfizer's Fair Value will decrease by 26.7%, to a mere $44.91.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
6
|
$149.11 | $152.52 | 12.5% | 19 |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
3
|
£104.94 | £136.08 | 39% | 13 |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
7
|
$113.77 | $141.24 | 23.06% | 19 |
| COST Stock Forecast | Costco Wholesale | Outperform |
6
|
$437.71 | $584.00 | 34.11% | 12 |
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
8
|
$77.13 | $76.69 | 1.13% | 16 |
Pfizer Revenue Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's Revenue has grown by 99.11%, from $40.83B to $81.29B. For the next year, analysts are expecting Revenue to reach a reasonable $105.90B – an increase of 30.28%. By 2030, professionals predict that Pfizer's Revenue will decrease by 34.71%, to a mere $53.07B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| AMGN Stock Forecast | Amgen | Hold |
6
|
$251.89 | $246.46 | -0.75% | 13 |
| CSL Stock Forecast | CSL | Outperform |
4
|
$266.28 | $228.01 | -14.01% | 10 |
| MMM Stock Forecast | 3M | Hold |
5
|
$145.75 | $188.41 | 9.98% | 17 |
Pfizer Dividend per Share Forecast for 2022 - 2025 - 2030
In the past three years, Pfizer's DPS has seen a tremendous increase, going from $1.36 to $1.56 – an increase of 14.71%. Next year, analysts are expecting DPS to reach $1.62 – an increase of 3.85%. Over the next nine years, the forecast is for DPS to grow by 8.33%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
5
|
$257.45 | $270.20 | 10.7% | 3 |
| BAYN Stock Forecast | Bayer | Outperform |
5
|
63.29€ | 67.79€ | 20.08% | 14 |
| CL Stock Forecast | Colgate-Palmolive | Hold |
5
|
$78.12 | $84.90 | 4.97% | 9 |
Pfizer Free Cash Flow Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's Free Cash Flow has grown by 115.77%, rising from $13.84B to $29.87B. For next year, analysts predict earnings per share of $34.79B, which would mean an increase of 16.47%. In 2030, professionals predict that Pfizer's Free Cash Flow will decrease by 49.08%, reaching $15.21B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
3
|
¥3.79k | ¥0.00 | 18.73% | 0 |
| BAS Stock Forecast | BASF | Outperform |
5
|
48.76€ | 78.27€ | 31.26% | 16 |
| BNTX Stock Forecast | BioNTech | Hold |
0
|
$284.21 | $0.00 | -11.75% | 3 |
Pfizer Net Income Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's Net Income has grown by 97.07%, rising from $11.15B to $21.98B. For next year, analysts predict earnings per share of $40.98B, which would mean an increase of 86.43%. According to professionals, by 2030, Pfizer's Net Income will have decreased by 14.38%, falling all the way down to $18.82B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
2
|
¥2.83k | ¥0.00 | 36.07% | 0 |
| ALC Stock Forecast | Alcon | Outperform |
0
|
CHF79.00 | CHF0.00 | 15.3% | 14 |
| BAX Stock Forecast | Baxter International | Outperform |
5
|
$73.90 | $92.47 | 21.79% | 3 |
Pfizer EBITDA Forecast for 2022 - 2025 - 2030
In the past three years, Pfizer's EBITDA has seen significant growth, rising from $13.47B to $31.95B – a growth of 137.24%. In the next year, analysts believe that EBITDA will reach an impressive $48.44B – an increase of 51.62%. By 2030, professionals believe that Pfizer's EBITDA will have decreased by an astonishing 39.14%, plummeting to just $19.44B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| A Stock Forecast | Agilent Technologies | Outperform |
7
|
$124.41 | $172.40 | 28.61% | 2 |
| BN Stock Forecast | Danone | Hold |
4
|
54.87€ | 62.59€ | 2.06% | 18 |
| BIIB Stock Forecast | Biogen | Outperform |
4
|
$202.54 | $287.21 | 12.32% | 24 |
Pfizer EBIT Forecast for 2022 - 2025 - 2030
Pfizer's EBIT has seen astonishing growth in the last three years, rising from $7.36B to $26.85B – a growth of 264.99%. In the next year, analysts believe that EBIT will reach an impressive $44.31B – an increase of 65.07%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| 4503 Stock Forecast | Astellas Pharma | Outperform |
2
|
¥1.80k | ¥0.00 | 33.33% | 0 |
| CHD Stock Forecast | Church & Dwight | Hold |
5
|
$90.43 | $88.52 | 9.48% | 9 |
| ERF Stock Forecast | Eurofins Scientific | Hold |
2
|
86.95€ | 0.00€ | 20.76% | 10 |
Pfizer EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the last three years, Pfizer's EPS has grown by 47.33%, from $3.00 to $4.42. For the next year, analysts are expecting EPS to reach an impressive $7.14 – an increase of 61.54%. By 2030, professionals predict that Pfizer's EPS will decrease by 26.7%, to a mere $3.24.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals | Outperform |
0
|
$127.05 | $209.00 | 60.96% | 10 |
| 4523 Stock Forecast | Eisai | Hold |
0
|
¥6.85k | ¥0.00 | -3.61% | 0 |
| CRDA Stock Forecast | Croda International Plc | Outperform |
3
|
£67.30 | £85.37 | 29.27% | 13 |